We are live on ! Find out more
PDLI

PDL BioPharma, Inc.
PDLI

Delisted

PDLI was delisted on the 30th of December, 2020.

Back to rankings

176 hedge funds and large institutions have $394M invested in PDL BioPharma, Inc. in 2018 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 47 increasing their positions, 65 reducing their positions, and 27 closing their positions.

New
Increased
Maintained
Reduced
Closed

5% more call options, than puts

Call options by funds: $214K | Put options by funds: $204K

2% more capital invested

Capital invested by funds: $387M → $394M (+$7.39M)

6% less funds holding

Funds holding: 187 → 176 (-11)

28% less repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 65

33% less first-time investments, than exits

New positions opened: 18 | Existing positions closed: 27

Holders
176
Holders Change
-11
Holders Change %
-5.88%
% of All Funds
4.03%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
18
Increased
47
Reduced
65
Closed
27
Calls
$214K
Puts
$204K
Net Calls
+$10K
Net Calls Change
+$212K

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$4.37M
2
Northern Trust
Northern Trust
Illinois
+$4.31M
3
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L)
British Columbia, Canada
+$3.12M
4
Dimensional Fund Advisors
Dimensional Fund Advisors
Texas
+$3.08M
5
Invesco
Invesco
Georgia
+$2.76M

Top Sellers

Rank Fund Capital Flow
1
Morgan Stanley
Morgan Stanley
New York
-$6.39M
2
Norges Bank
Norges Bank
Norway
-$3.76M
3
Millennium Management
Millennium Management
New York
-$3.61M
4
State Street
State Street
Massachusetts
-$2.78M
5
SCP
Seizert Capital Partners
Michigan
-$2.77M
Name Holding Trade Value Shares
Change 		Change in
Stake
Ameriprise
51
Ameriprise
Minnesota
$948K -$157K -57,449 -15%
Macquarie Group
52
Macquarie Group
Australia
$882K +$18.6K +6,800 +2%
TA
53
Teachers Advisors
New York
$873K – – –
Axa
54
Axa
France
$842K -$143K -52,300 -15%
AG
55
Aperio Group
California
$819K +$29.6K +10,857 +4%
Swiss National Bank
56
Swiss National Bank
Switzerland
$791K – – –
AllianceBernstein
57
AllianceBernstein
Tennessee
$771K +$35.8K +13,100 +5%
Millennium Management
58
Millennium Management
New York
$754K -$3.61M -1,321,065 -84%
CS
59
Credit Suisse
Switzerland
$738K -$175K -64,205 -20%
Credit Agricole
60
Credit Agricole
France
$736K – – –
SO
61
STRS Ohio
Ohio
$726K – – –
JP Morgan Chase
62
JP Morgan Chase
New York
$683K -$954K -349,364 -60%
California State Teachers Retirement System (CalSTRS)
63
California State Teachers Retirement System (CalSTRS)
California
$683K -$46K -16,844 -7%
SCA
64
Secor Capital Advisors
New York
$677K -$3.89K -1,425 -0.6%
FIM
65
Freedom Investment Management
Connecticut
$655K +$3.46K +1,268 +0.6%
MSL
66
Mackay Shields LLC
New York
$645K +$599K +219,296 New
ECM
67
Element Capital Management
New York
$626K +$581K +212,846 New
DekaBank Deutsche Girozentrale
68
DekaBank Deutsche Girozentrale
Germany
$571K -$5.46K -2,000 -1%
New York State Common Retirement Fund
69
New York State Common Retirement Fund
New York
$539K – – –
RC
70
RBF Capital
California
$508K – – –
Citigroup
71
Citigroup
New York
$502K -$351K -128,637 -43%
RhumbLine Advisers
72
RhumbLine Advisers
Massachusetts
$486K -$16.1K -5,916 -3%
SCP
73
Seizert Capital Partners
Michigan
$476K -$2.77M -1,013,781 -86%
SAM
74
Shell Asset Management
Netherlands
$455K – – –
Fidelity Investments
75
Fidelity Investments
Massachusetts
$446K – – –
1 2
3
4 5

PDLI Hedge Fund Activity: Q1 2018 in Review

176 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in PDL BioPharma, Inc. (PDLI) for Q1 2018, worth a combined $394M — up 1.9% from $387M a quarter earlier.

Sellers outnumbered buyers: 27 funds closed out of PDLI and 18 opened new positions — a net loss of 9 holders — while 65 trimmed existing stakes and 47 added.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $4.37M. The largest seller was Morgan Stanley, cutting an estimated $6.39M.

  • 176 institutional investors held PDL BioPharma, Inc. (PDLI) as of Q1 2018, down from 187 in Q4 2017.
  • Funds reported $394M of PDL BioPharma, Inc. stock for Q1 2018, up 1.9% quarter-over-quarter.
  • 18 funds opened new PDL BioPharma, Inc. positions in Q1 2018 and 27 closed out, a net change of -9 holders.
  • The largest PDL BioPharma, Inc. buyer in Q1 2018 was Citadel Advisors, an estimated $4.37M added.
  • The largest PDL BioPharma, Inc. seller in Q1 2018 was Morgan Stanley, an estimated $6.39M sold.

Based on aggregated 13F filings for Q1 2018.